AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
J Med Chem. 2013 Aug 8;56(15):6175-89. doi: 10.1021/jm400644z. Epub 2013 Jul 26.
We have analyzed the protein-binding pharmacophore of NAD and its close analogues in all protein-ligand structures available in the RCSB database as of February 2012; this analysis has then been used to assess the novelty of structures emerging after that date. We show that proteins have evolved diverse pharmacophore motifs for binding the adenine moiety, fewer, but still diverse, motifs for nicotinamide, and a very limited set of motifs for binding the pyrophosphate linker. Our exhaustive analysis includes a pharmacophore contact analysis for over 1900 protein-ligand structures containing NAD analogues; we have benchmarked this set of contacts against nearly 27 000 protein-ligand structures to demonstrate that the diversity of interactions seen with NAD is very similar to that seen for all other ligands. Hence, variation in binding motifs for NAD is not distinct from that observed for other ligands and they show significant variation across protein families.
我们分析了截至 2012 年 2 月 RCSB 数据库中所有蛋白-配体结构中 NAD 及其类似物的蛋白结合药效团;然后,我们使用该分析来评估该日期之后出现的结构的新颖性。我们表明,蛋白质已经进化出了多种结合腺嘌呤部分的药效团基序,结合烟酰胺的基序较少,但仍然多样化,结合焦磷酸链接的基序非常有限。我们的详尽分析包括对包含 NAD 类似物的 1900 多个蛋白-配体结构的药效团接触分析;我们已经针对近 27000 个蛋白-配体结构对这组接触进行了基准测试,以证明与 NAD 相关的相互作用的多样性与所有其他配体非常相似。因此,NAD 的结合基序的变化与其他配体观察到的变化没有明显区别,并且它们在蛋白家族之间表现出显著的变化。